mScarlet/LUC Reporter Cell Line - BT-474

The BT-474 cell line is a highly characterized human model of breast carcinoma, originally isolated from a solid, invasive ductal tumor of the breast. It serves as a cornerstone in mammary oncology research, particularly valued for its robust co-expression of the estrogen receptor (ER), progesterone receptor (PR), and an exceptional amplification of the human epidermal growth factor receptor 2 (HER2), making it a classic model of HER2-positive, luminal B breast cancer. The mScarlet/Luc Reporter Cell Line - BT-474 is a sophisticated, stably transfected derivative explicitly engineered to simultaneously co-express both the exceptionally bright, monomeric red fluorescent protein mScarlet and firefly luciferase (Luc). This advanced dual-labeling construct ensures continuous, high-level expression of both functional reporter genes across sequential in vitro passages. Crucially, this stable genetic integration is achieved without compromising the fundamental epithelial morphology, the distinct ER/PR/HER2-positive molecular profile, or the intrinsic tumorigenic capacity of the original parental BT-474 cells.

The incorporation of this dual-reporter system significantly broadens the experimental utility of the BT-474 model for comprehensive translational breast cancer research. For in vitro studies, the intense red fluorescence provided by mScarlet expression allows researchers to easily visualize cellular dynamics, accurately quantify proliferation rates, and seamlessly isolate specific cellular subpopulations using standard fluorescence microscopy and flow cytometry techniques. For in vivo applications, the robust luciferase activity serves as the optimal foundation for non-invasive, longitudinal tracking of primary tumor progression through bioluminescence imaging (BLI). Because it is a human-derived cell line, the BT-474-mScarlet/Luc model is typically engrafted into immunocompromised mice (such as athymic nude or NSG strains, often requiring exogenous estrogen supplementation for optimal growth) to establish highly reliable subcutaneous xenografts or clinically relevant orthotopic mammary fat pad models. This specialized reporter line represents an exceptionally valuable platform for evaluating the in vivo therapeutic efficacy of novel chemotherapeutic regimens, targeted pharmacological compounds (specifically HER2-directed monoclonal antibodies and tyrosine kinase inhibitors), and endocrine therapies, facilitating the real-time, accurate quantification of localized tumor burden and disease progression in living subjects.